Recent posts

TypePostAuthorRepliesLast updated
Blog entryKEI statement: 21st meeting of the WHO Expert Committee on the Selection and Use of Essential Medicines thiru019 hours 49 min ago
Blog entryDr. Elias Zerhouni defends Sanofi/Army proposed license on Zika patents, and KEI responds James Love05 days 16 hours ago
Blog entry14 March 2017 - Senate Finance Committee grills Robert Lighthizer (USTR nominee) on trade and IPR policies thiru06 days 2 hours ago
Blog entryMaryland House of Delegates passes bill on prescription drug price gouging by vote of 137 to 4 James Love06 days 13 hours ago
Blog entryLeaked: Three documents from RCEP negotiations James Love06 days 16 hours ago
Blog entryLeaked document: March 15, 2017 Note by Switzerland on India EFTA TEPA IP Chapter James Love06 days 16 hours ago
Blog entryPatients, Members of Congress Ask Chilean Government to Issue Compulsory Licenses on Prostate Cancer and HCV Drug Patents Zack Struver06 days 17 hours ago
Blog entryKEI Testifies in Maryland on Drug R&D Cost Transparency Bill (HB666/SB437) Zack Struver01 week 4 days ago
PageResearch and Development Cost Transparency Legislation Zack Struver01 week 4 days ago
Blog entryHHS Office of Inspector General Declines to Investigate Failure to Disclose Federal Funding in Ionis Pharmaceuticals' Spinraza Zack Struver01 week 4 days ago
Blog entrySpinraza: KEI asks DHHS Office of the Inspector General (OIG) to investigate a failure to disclose federal funding in patents James Love01 week 4 days ago
Book pageJames Love, Director James Love01 week 5 days ago
Blog entryCompany disclosures of R&D costs on SEC filings James Love02 weeks 17 hours ago
PageZika James Love02 weeks 17 hours ago
Blog entryKEI 10 March 2017 Comments on Army Exclusive License on Zika Virus Vaccine Patents to Sanofi KEI Staff02 weeks 18 hours ago
Blog entryDHHS declared public health emergency for Zika virus James Love02 weeks 3 days ago
Book pageKEI Board of Directors KEI Staff02 weeks 3 days ago
Blog entry2017 R&D Cost Transparency Proposals in the United States Zack Struver02 weeks 3 days ago
Blog entry8 March 2017 - Statement of Portugal - HRC 34 - Panel on Access to Medicines thiru02 weeks 3 days ago
Blog entry8 March 2017 - Human Rights Council's Access to Medicines panel set to discuss Report of UN HLP thiru02 weeks 4 days ago
Blog entry8 March 2017 - Statement of the European Union - HRC 34 - Panel on Access to Medicines thiru02 weeks 5 days ago
Blog entry8 March 2017 - Statement of the World Trade Organization - HRC 34 - Panel on Access to Medicines thiru02 weeks 5 days ago
Blog entry8 March 2017 - Statement of Deputy High Commissioner (Kate Gilmore, OHCHR) on the Right to Health thiru02 weeks 5 days ago
Blog entryKEI Submission to Oregon Senate on R&D Cost Transparency Provisions in SB 793 Zack Struver02 weeks 5 days ago
Blog entryFeb 24, 2017 - U.S. History, Experiences, and Prospects of Compulsory Licensing of Medical Patents Claire Cassedy02 weeks 6 days ago